Champions Oncology (CSBR) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
28 Aug, 2026Executive summary
Annual meeting scheduled for October 14, 2026, at 9:00 a.m. in Hackensack, New Jersey.
Shareholders of record as of August 21, 2026, are entitled to vote.
Proxy materials are available online, with paper copies available upon request before September 30, 2026.
Voting matters and shareholder proposals
Election of seven Board of Director nominees for the ensuing year.
Ratification of EisnerAmper LLP as independent registered public accounting firm for fiscal year ending April 30, 2027.
Advisory vote on executive compensation and on the frequency of such votes.
Approval of the 2026 Equity Incentive Plan.
Other business may be transacted as properly brought before the meeting.
Board of directors and corporate governance
Seven director nominees are up for election to serve until successors are elected and qualified or until earlier death, resignation, or removal.
Latest events from Champions Oncology
- Proxy covers director elections, auditor ratification, say-on-pay, and a new equity incentive plan.CSBR
Proxy filing - Record revenue and positive adjusted EBITDA achieved, with core services growth and margin gains.CSBR
Q4 2026 - Record study service revenue and positive adjusted EBITDA, with margin improvement expected.CSBR
Q3 2026 - Quarterly revenue up 11–11.5% to $15M, margin at 52%, and adjusted EBITDA near $843K.CSBR
Q2 2026 - Q1 revenue was $14.0M, with margin pressure, net loss, and positive cash flow from operations.CSBR
Q1 2026 - Q2 revenue up 17% to $13.5M, with margin gains and new data licensing amid liquidity risks.CSBR
Q2 2025 - Revenue up 12% and return to profitability, but liquidity and going concern risks remain.CSBR
Q1 2025 - Q4 revenue up 7% and adjusted EBITDA positive, signaling improved outlook.CSBR
Q4 2024 - Record revenue and net income driven by data licensing and operational efficiency.CSBR
Q3 2025